DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape
April 17, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 17, 2023 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape Crohn’s...
Expanding Government Assistance is Controlling the Market, Microbiome Therapeutics Market to Grow By 32% CAGR through 2032, Says Fact.MR
December 08, 2022 09:00 ET
|
FACT.MR
Rockville, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The microbiome therapeutics market size is estimated at US$ 112.20 Bn in 2022 and is anticipated to grow at a CAGR of 32% from 2022 to 2032. The...
Palmetto Infusion, leading infusion provider in southeast, opens first clinic in Florida
December 05, 2022 10:23 ET
|
Palmetto Infusion
Panama City, Florida, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Palmetto Infusion, the leading ambulatory infusion provider in the southeast, today announces a new clinic opening in Panama City—the first in...
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Colorectal Procedure Market to Garner $29.55Bn, Globally, by 2028 Growing at 13.1% CAGR | Exclusive Report by The Insight Partners
August 24, 2022 05:16 ET
|
The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Colorectal Procedure Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product,...
Organovo Achieves 3D Tissue Model for Crohn’s Disease
May 17, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel...
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
April 27, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
September 14, 2021 07:30 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
September 13, 2021 06:00 ET
|
AzurRx BioPharma, Inc.
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to GI...